Renal Cell Cancer Treatment Market, Global Outlook and Forecast 2022-2028

March 2022 | 101 pages | ID: RD1510948C80EN
Market Monitor Global

Abstracts

Renal Cell Cancer Treatment -- also called renal cancer -- is a disease in which kidney cells become malignant (cancerous) and grow out of control, forming a tumor. Almost all kidney cancers first appear in the lining of tiny tubes (tubules) in the kidney. This type of kidney cancer is called renal cell carcinoma.

Renal cell carcinoma (RCC) is a common malignant tumor worldwide, referred to as kidney cancer. According to the World Health Organization, the global incidence of kidney cancer accounts for 2% to 3% of systemic tumors. Among malignant tumors of the urinary system, its incidence is second only to bladder cancer, and it is increasing year by year. In recent years, targeted therapy and precision therapy have become standard treatments for kidney cancer.

This report contains market size and forecasts of Renal Cell Cancer Treatment in Global, including the following market information:

Global Renal Cell Cancer Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Renal Cell Cancer Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Monoclonal Antibody Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Renal Cell Cancer Treatment include Pfizer, Bristol-Myers Squibb, Roche, GSK, Novartis, Bayer, Merck & Co., Exelixis and Takeda, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Renal Cell Cancer Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Renal Cell Cancer Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Renal Cell Cancer Treatment Market Segment Percentages, by Type, 2021 (%)

• Monoclonal Antibody
• mTOR Inhibitors
• Kinase Inhibitors
• Other

Global Renal Cell Cancer Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Renal Cell Cancer Treatment Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Pharmacy
• Other

Global Renal Cell Cancer Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Renal Cell Cancer Treatment Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Renal Cell Cancer Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Renal Cell Cancer Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Pfizer
• Bristol-Myers Squibb
• Roche
• GSK
• Novartis
• Bayer
• Merck & Co.
• Exelixis
• Takeda
• Eisai
• CTTQ
• AVEO Oncology
• Everest Pharm
• Cipla
• NATCO
• Beacon Pharma
• SAMARTH

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Renal Cell Cancer Treatment Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Renal Cell Cancer Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL RENAL CELL CANCER TREATMENT OVERALL MARKET SIZE

2.1 Global Renal Cell Cancer Treatment Market Size: 2021 VS 2028
2.2 Global Renal Cell Cancer Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Renal Cell Cancer Treatment Players in Global Market
3.2 Top Global Renal Cell Cancer Treatment Companies Ranked by Revenue
3.3 Global Renal Cell Cancer Treatment Revenue by Companies
3.4 Top 3 and Top 5 Renal Cell Cancer Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Renal Cell Cancer Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Renal Cell Cancer Treatment Players in Global Market
  3.6.1 List of Global Tier 1 Renal Cell Cancer Treatment Companies
  3.6.2 List of Global Tier 2 and Tier 3 Renal Cell Cancer Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Renal Cell Cancer Treatment Market Size Markets, 2021 & 2028
  4.1.2 Monoclonal Antibody
  4.1.3 mTOR Inhibitors
  4.1.4 Kinase Inhibitors
  4.1.5 Other
4.2 By Type - Global Renal Cell Cancer Treatment Revenue & Forecasts
  4.2.1 By Type - Global Renal Cell Cancer Treatment Revenue, 2017-2022
  4.2.2 By Type - Global Renal Cell Cancer Treatment Revenue, 2023-2028
  4.2.3 By Type - Global Renal Cell Cancer Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Renal Cell Cancer Treatment Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Pharmacy
  5.1.4 Other
5.2 By Application - Global Renal Cell Cancer Treatment Revenue & Forecasts
  5.2.1 By Application - Global Renal Cell Cancer Treatment Revenue, 2017-2022
  5.2.2 By Application - Global Renal Cell Cancer Treatment Revenue, 2023-2028
  5.2.3 By Application - Global Renal Cell Cancer Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Renal Cell Cancer Treatment Market Size, 2021 & 2028
6.2 By Region - Global Renal Cell Cancer Treatment Revenue & Forecasts
  6.2.1 By Region - Global Renal Cell Cancer Treatment Revenue, 2017-2022
  6.2.2 By Region - Global Renal Cell Cancer Treatment Revenue, 2023-2028
  6.2.3 By Region - Global Renal Cell Cancer Treatment Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Renal Cell Cancer Treatment Revenue, 2017-2028
  6.3.2 US Renal Cell Cancer Treatment Market Size, 2017-2028
  6.3.3 Canada Renal Cell Cancer Treatment Market Size, 2017-2028
  6.3.4 Mexico Renal Cell Cancer Treatment Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Renal Cell Cancer Treatment Revenue, 2017-2028
  6.4.2 Germany Renal Cell Cancer Treatment Market Size, 2017-2028
  6.4.3 France Renal Cell Cancer Treatment Market Size, 2017-2028
  6.4.4 U.K. Renal Cell Cancer Treatment Market Size, 2017-2028
  6.4.5 Italy Renal Cell Cancer Treatment Market Size, 2017-2028
  6.4.6 Russia Renal Cell Cancer Treatment Market Size, 2017-2028
  6.4.7 Nordic Countries Renal Cell Cancer Treatment Market Size, 2017-2028
  6.4.8 Benelux Renal Cell Cancer Treatment Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Renal Cell Cancer Treatment Revenue, 2017-2028
  6.5.2 China Renal Cell Cancer Treatment Market Size, 2017-2028
  6.5.3 Japan Renal Cell Cancer Treatment Market Size, 2017-2028
  6.5.4 South Korea Renal Cell Cancer Treatment Market Size, 2017-2028
  6.5.5 Southeast Asia Renal Cell Cancer Treatment Market Size, 2017-2028
  6.5.6 India Renal Cell Cancer Treatment Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Renal Cell Cancer Treatment Revenue, 2017-2028
  6.6.2 Brazil Renal Cell Cancer Treatment Market Size, 2017-2028
  6.6.3 Argentina Renal Cell Cancer Treatment Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Renal Cell Cancer Treatment Revenue, 2017-2028
  6.7.2 Turkey Renal Cell Cancer Treatment Market Size, 2017-2028
  6.7.3 Israel Renal Cell Cancer Treatment Market Size, 2017-2028
  6.7.4 Saudi Arabia Renal Cell Cancer Treatment Market Size, 2017-2028
  6.7.5 UAE Renal Cell Cancer Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer
  7.1.1 Pfizer Corporate Summary
  7.1.2 Pfizer Business Overview
  7.1.3 Pfizer Renal Cell Cancer Treatment Major Product Offerings
  7.1.4 Pfizer Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.1.5 Pfizer Key News
7.2 Bristol-Myers Squibb
  7.2.1 Bristol-Myers Squibb Corporate Summary
  7.2.2 Bristol-Myers Squibb Business Overview
  7.2.3 Bristol-Myers Squibb Renal Cell Cancer Treatment Major Product Offerings
  7.2.4 Bristol-Myers Squibb Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.2.5 Bristol-Myers Squibb Key News
7.3 Roche
  7.3.1 Roche Corporate Summary
  7.3.2 Roche Business Overview
  7.3.3 Roche Renal Cell Cancer Treatment Major Product Offerings
  7.3.4 Roche Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.3.5 Roche Key News
7.4 GSK
  7.4.1 GSK Corporate Summary
  7.4.2 GSK Business Overview
  7.4.3 GSK Renal Cell Cancer Treatment Major Product Offerings
  7.4.4 GSK Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.4.5 GSK Key News
7.5 Novartis
  7.5.1 Novartis Corporate Summary
  7.5.2 Novartis Business Overview
  7.5.3 Novartis Renal Cell Cancer Treatment Major Product Offerings
  7.5.4 Novartis Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.5.5 Novartis Key News
7.6 Bayer
  7.6.1 Bayer Corporate Summary
  7.6.2 Bayer Business Overview
  7.6.3 Bayer Renal Cell Cancer Treatment Major Product Offerings
  7.6.4 Bayer Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.6.5 Bayer Key News
7.7 Merck & Co.
  7.7.1 Merck & Co. Corporate Summary
  7.7.2 Merck & Co. Business Overview
  7.7.3 Merck & Co. Renal Cell Cancer Treatment Major Product Offerings
  7.7.4 Merck & Co. Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.7.5 Merck & Co. Key News
7.8 Exelixis
  7.8.1 Exelixis Corporate Summary
  7.8.2 Exelixis Business Overview
  7.8.3 Exelixis Renal Cell Cancer Treatment Major Product Offerings
  7.8.4 Exelixis Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.8.5 Exelixis Key News
7.9 Takeda
  7.9.1 Takeda Corporate Summary
  7.9.2 Takeda Business Overview
  7.9.3 Takeda Renal Cell Cancer Treatment Major Product Offerings
  7.9.4 Takeda Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.9.5 Takeda Key News
7.10 Eisai
  7.10.1 Eisai Corporate Summary
  7.10.2 Eisai Business Overview
  7.10.3 Eisai Renal Cell Cancer Treatment Major Product Offerings
  7.10.4 Eisai Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.10.5 Eisai Key News
7.11 CTTQ
  7.11.1 CTTQ Corporate Summary
  7.11.2 CTTQ Business Overview
  7.11.3 CTTQ Renal Cell Cancer Treatment Major Product Offerings
  7.11.4 CTTQ Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.11.5 CTTQ Key News
7.12 AVEO Oncology
  7.12.1 AVEO Oncology Corporate Summary
  7.12.2 AVEO Oncology Business Overview
  7.12.3 AVEO Oncology Renal Cell Cancer Treatment Major Product Offerings
  7.12.4 AVEO Oncology Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.12.5 AVEO Oncology Key News
7.13 Everest Pharm
  7.13.1 Everest Pharm Corporate Summary
  7.13.2 Everest Pharm Business Overview
  7.13.3 Everest Pharm Renal Cell Cancer Treatment Major Product Offerings
  7.13.4 Everest Pharm Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.13.5 Everest Pharm Key News
7.14 Cipla
  7.14.1 Cipla Corporate Summary
  7.14.2 Cipla Business Overview
  7.14.3 Cipla Renal Cell Cancer Treatment Major Product Offerings
  7.14.4 Cipla Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.14.5 Cipla Key News
7.15 NATCO
  7.15.1 NATCO Corporate Summary
  7.15.2 NATCO Business Overview
  7.15.3 NATCO Renal Cell Cancer Treatment Major Product Offerings
  7.15.4 NATCO Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.15.5 NATCO Key News
7.16 Beacon Pharma
  7.16.1 Beacon Pharma Corporate Summary
  7.16.2 Beacon Pharma Business Overview
  7.16.3 Beacon Pharma Renal Cell Cancer Treatment Major Product Offerings
  7.16.4 Beacon Pharma Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.16.5 Beacon Pharma Key News
7.17 SAMARTH
  7.17.1 SAMARTH Corporate Summary
  7.17.2 SAMARTH Business Overview
  7.17.3 SAMARTH Renal Cell Cancer Treatment Major Product Offerings
  7.17.4 SAMARTH Renal Cell Cancer Treatment Revenue in Global Market (2017-2022)
  7.17.5 SAMARTH Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Renal Cell Cancer Treatment Market Opportunities & Trends in Global Market
Table 2. Renal Cell Cancer Treatment Market Drivers in Global Market
Table 3. Renal Cell Cancer Treatment Market Restraints in Global Market
Table 4. Key Players of Renal Cell Cancer Treatment in Global Market
Table 5. Top Renal Cell Cancer Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Renal Cell Cancer Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Renal Cell Cancer Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Renal Cell Cancer Treatment Product Type
Table 9. List of Global Tier 1 Renal Cell Cancer Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Renal Cell Cancer Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Renal Cell Cancer Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Renal Cell Cancer Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Renal Cell Cancer Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Renal Cell Cancer Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Renal Cell Cancer Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Renal Cell Cancer Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Renal Cell Cancer Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Renal Cell Cancer Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Renal Cell Cancer Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Renal Cell Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Renal Cell Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Renal Cell Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Renal Cell Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Renal Cell Cancer Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer Corporate Summary
Table 31. Pfizer Renal Cell Cancer Treatment Product Offerings
Table 32. Pfizer Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Bristol-Myers Squibb Corporate Summary
Table 34. Bristol-Myers Squibb Renal Cell Cancer Treatment Product Offerings
Table 35. Bristol-Myers Squibb Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Roche Corporate Summary
Table 37. Roche Renal Cell Cancer Treatment Product Offerings
Table 38. Roche Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 39. GSK Corporate Summary
Table 40. GSK Renal Cell Cancer Treatment Product Offerings
Table 41. GSK Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Novartis Corporate Summary
Table 43. Novartis Renal Cell Cancer Treatment Product Offerings
Table 44. Novartis Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Bayer Corporate Summary
Table 46. Bayer Renal Cell Cancer Treatment Product Offerings
Table 47. Bayer Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Merck & Co. Corporate Summary
Table 49. Merck & Co. Renal Cell Cancer Treatment Product Offerings
Table 50. Merck & Co. Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Exelixis Corporate Summary
Table 52. Exelixis Renal Cell Cancer Treatment Product Offerings
Table 53. Exelixis Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Takeda Corporate Summary
Table 55. Takeda Renal Cell Cancer Treatment Product Offerings
Table 56. Takeda Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Eisai Corporate Summary
Table 58. Eisai Renal Cell Cancer Treatment Product Offerings
Table 59. Eisai Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 60. CTTQ Corporate Summary
Table 61. CTTQ Renal Cell Cancer Treatment Product Offerings
Table 62. CTTQ Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 63. AVEO Oncology Corporate Summary
Table 64. AVEO Oncology Renal Cell Cancer Treatment Product Offerings
Table 65. AVEO Oncology Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 66. Everest Pharm Corporate Summary
Table 67. Everest Pharm Renal Cell Cancer Treatment Product Offerings
Table 68. Everest Pharm Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 69. Cipla Corporate Summary
Table 70. Cipla Renal Cell Cancer Treatment Product Offerings
Table 71. Cipla Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 72. NATCO Corporate Summary
Table 73. NATCO Renal Cell Cancer Treatment Product Offerings
Table 74. NATCO Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 75. Beacon Pharma Corporate Summary
Table 76. Beacon Pharma Renal Cell Cancer Treatment Product Offerings
Table 77. Beacon Pharma Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)
Table 78. SAMARTH Corporate Summary
Table 79. SAMARTH Renal Cell Cancer Treatment Product Offerings
Table 80. SAMARTH Renal Cell Cancer Treatment Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Renal Cell Cancer Treatment Segment by Type in 2021
Figure 2. Renal Cell Cancer Treatment Segment by Application in 2021
Figure 3. Global Renal Cell Cancer Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Renal Cell Cancer Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Renal Cell Cancer Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Renal Cell Cancer Treatment Revenue in 2021
Figure 8. By Type - Global Renal Cell Cancer Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Renal Cell Cancer Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Renal Cell Cancer Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Renal Cell Cancer Treatment Revenue Market Share, 2017-2028
Figure 12. US Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Renal Cell Cancer Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Renal Cell Cancer Treatment Revenue Market Share, 2017-2028
Figure 24. China Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Renal Cell Cancer Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Renal Cell Cancer Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Renal Cell Cancer Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bristol-Myers Squibb Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Roche Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. GSK Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Novartis Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Bayer Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Merck & Co. Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Exelixis Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Takeda Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Eisai Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. CTTQ Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. AVEO Oncology Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Everest Pharm Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Cipla Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. NATCO Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Beacon Pharma Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. SAMARTH Renal Cell Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)